Asia Pacific Antiviral Drug Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Antiviral Drugs are medicines which are used for treating viral infections. Most anti-viral drugs are used for particular viral diseases, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen. Instead, they hinder the development of those viruses.

Asia-Pacific Antiviral Drugs Market Segments Size & Growth:

Asia-Pacific Antiviral drug market size is projected to reach approximately $8.2 billion by the end of 2024 with a CAGR of close to 7.3% from $5.9 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Increased Nanotechnology in Developing Antiviral Agents, Technical breakthroughs in the development of Antivirals, Increasing Unmet Needs and Population Growth. However, High Risk of Failure and Government Firmness, Increasing Market for Generics, Lack of a broad antiviral to treat multiple viral infections are thereby hampering the market growth.

Asia-Pacific Antiviral Drugs Market Segments Share:

Asia-Pacific Antiviral Drugs Market is categorised into a therapeutic area which comprises of HIV/AIDS Therapeutics Market, Hepatitis Therapeutics Market, Herpes Therapeutics Market, Influenza Therapeutics Market. Among the Therapeutic area, HIV/AIDS Therapeutics Market segment dominated the market in 2018. By Type, the market is segregated into branded and genetics. Among the Type, Genetics segment is projected to continue its dominant during the period 2018-2024. By Geography, India and China are expected to dominate the Asia-Pacific Antiviral Drugs market, and the growth in the Asia-Pacific economies is mainly attributed because of huge profit margins and growth prospects.

Asia-Pacific Antiviral Drugs Market Trends:

• The new hybridoma technique is a novel approach toward the development of monoclonal antibodies, which are selective. This technique will not only have a positive impact on viral diseases but also decrease the cost of the overall treatment. It can be expected that antiviral agents, which were above USD 100 and could be used to control an epidemic efficiently, can now be produced at 1% of its original cost.
• The use of combination therapy has proven to be beneficial to treat certain viral infections due to their synergistic effect. This therapy helps to prevent drug resistance acquired by the viral organism as the treatment contains more than one drug. Most of the drugs employed in the treatment of HIV are given in combination with other drugs to combat the opportunistic infections in HIV patients.
• Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) had approved ISENTRESS, the company’s integrase inhibitor, for use in combination with other antiretroviral agents, for the treatment of HIV-1 in neonates – newborn patients from birth to four weeks of age – weighing at least 2 kg.

North America Antiviral Drugs Market Research Report:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
• Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• The primary market players, such as
• Merck & Co
• MedImmune
• Johnson & Johnson
• GlaxoSmithKline
• Abbott Laboratories